You are here

vamorolone

Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials

Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials

BioSpace

Jounce Therapeutics

Aurinia Pharmaceuticals

Flag link:

Santhera axes half its employees and sees CMO depart after PhIII DMD fail

Santhera axes half its employees and sees CMO depart after PhIII DMD fail

Endpoints

Duchenne Muscular Dystrophy

Flag link:

Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen

Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen

Fierce Biotech

Duchenne Muscular Dystrophy

Flag link:

Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove

Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove

Endpoints

Duchenne Muscular Dystrophy

clinical trials

Flag link: